NCT07033299View on ClinicalTrials.gov

The Safety, Efficacy, and Cellular Metabolic Kinetics of CT1192 in Treating Patients With Anti Neutrophil Cytoplasmic Antibody Associated Vasculitis

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

March 31, 2027

Conditions
ANCA Associated Vasculitis (AAV)
Interventions
BIOLOGICAL

CAR-T Therapy

CT1192 cells infusion

Trial Locations (1)

China

Wuhan Union Hospita, Wuhan

Sponsors
All Listed Sponsors
collaborator

CARsgen Therapeutics Co., Ltd.

INDUSTRY

lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER